Clinical Trial: Immunoreactivity to Cetuximab in Cancer Patients
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Immunoreactivity to Cetuximab in Cancer Patients
Brief Summary:
RATIONALE: Studying samples of blood in the laboratory may help doctors predict which patients will develop hypersensitivity to cetuximab.
PURPOSE: This research study is looking at hypersensitivity to cetuximab in patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab.
Detailed Summary:
OBJECTIVES:
- To examine serum samples from patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab for the presence of antibodies against cetuximab.
OUTLINE: Serum samples are examined by immunoreactivity screening of IgE, IgG, IgA, and IgM antibodies and complement reaction.
Sponsor: Vanderbilt-Ingram Cancer Center
Current Primary Outcome: Identification of antibodies (e.g., IgE, IgG, IgA, and IgM) against cetuximab [ Time Frame: Until all samples are collected. ]
Original Primary Outcome: Identification of antibodies (e.g., IgE, IgG, IgA, and IgM) against cetuximab
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Vanderbilt-Ingram Cancer Center
Dates:
Date Received: May 9, 2009
Date Started: November 2006
Date Completion:
Last Updated: March 29, 2013
Last Verified: March 2013
